IPO momentum Leverage Mobia Medical’s 2026 IPO and substantial funding to positionVivistim as a capital-efficient, scalable solution for stroke rehabilitation programs seeking high-impact outcomes with clear reimbursement pathways.

Clinical leadership Target hospital systems and rehabilitation centers with newly appointed independent directors and a growing board to advocate for advanced neurostimulation therapy, emphasizing evidence of upper-limb motor gains in chronic stroke patients.

Revenue growth Capitalize on recent revenue growth and expanding commercial footprint to pursue enterprise deals with integrated medical device procurement programs, highlighting Vivistim’s FDA-approved implantable solution for moderate to severe impairments.

Strategic partnerships Identify collaboration opportunities with neurostimulation and rehabilitation device distributors, payer-focused partnerships, and post-acute care networks to broaden adoption, supported by strong regulatory clearance and safety information.

Market readiness Position Mobia Medical as a market leader in stroke recovery technology by aligning with private and public payer incentives, and emphasize the potential for neuroplasticity-driven motor improvements to drive favorable cost of care outcomes.